(INDV) Indivior Pharmaceuticals Inc BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(INDV) Indivior Pharmaceuticals Inc Complete Analysis Pack
See the Bigger Picture
This Indivior Pharmaceuticals Inc BCG Matrix is a company-specific strategy tool used to assess where its products or business units fall across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can see the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
SUBLOCADE: monthly depot leader
SUBLOCADE is Indivior Pharmaceuticals Inc’s clearest Star: a monthly buprenorphine depot for opioid use disorder that improves adherence versus daily pills. It generated about $1.1 billion in net revenue in 2024, showing strong demand and a leading niche position. Indivior still needs to fund access, promotion, and specialty distribution to protect that share.
U.S. long-acting buprenorphine
In FY2025, U.S. long-acting buprenorphine stayed Indivior Pharmaceuticals Inc’s fastest-growing commercial platform, led by the shift from daily oral maintenance to monthly extended-release treatment. The franchise is still in an expanding market, so sales reps and payer-access work remain critical. That growth-plus-investment profile is why it fits a Star in the BCG matrix.
OUD injectable maintenance segment
Indivior's OUD injectable maintenance business fits Star status because it serves a large, still-growing market built around 28-day dosing, which lifts persistence and cuts daily adherence burden. In the latest U.S. CDC count, overdose deaths stayed above 100,000, keeping treatment demand high, while monthly injectables keep gaining share versus daily oral therapy. Strong 2025 growth potential and durable retention support a high-growth, strong-positioning profile.
SPECIALTY PHARMACY CHANNEL
SUBLOCADE is sold through a controlled specialty pharmacy channel, which gives Indivior tighter control over access, inventory, and repeat dispensing. That matters for a long-use therapy: in 2024, SUBLOCADE generated about $1.03 billion in net revenue, so channel execution is a direct growth lever.
The specialty channel also helps manage patient starts and refill flow, which supports adherence and lowers leakage versus open distribution. For a high-growth brand, that makes the channel itself a strategic asset, not just a delivery step.
- Controlled access supports commercial control.
- Repeat dispensing helps keep patients on therapy.
- Channel scale supports SUBLOCADE growth.
BUPE DEPOT FRANCHISE
BUPE DEPOT FRANCHISE is Indivior Pharmaceuticals Inc’s Star asset because it is the main growth engine, with longer-acting buprenorphine standing apart from older transmucosal products. In FY2025, the depot franchise kept pushing the company’s mix toward branded, higher-value treatment, while the legacy daily products stayed the cash base.
This matters because Sublocade-type depot therapy is more innovative, supports better adherence, and has stronger long-term growth potential than short-acting options. That is why investors see the franchise as the core of Indivior Pharmaceuticals Inc’s future revenue mix.
- Star: high growth, high share
- Depot drives FY2025 mix shift
- More durable than older products
SUBLOCADE Drives Indivior’s FY2025 Growth
SUBLOCADE is Indivior Pharmaceuticals Inc’s Star: FY2025 long-acting buprenorphine stayed the main growth engine, with about $1.1 billion 2024 net revenue and strong 2025 momentum. The market is still expanding, and monthly dosing keeps winning on adherence. Specialty-pharmacy control also supports access and repeat fills.
| Star asset | FY2025 signal | Why it matters |
|---|---|---|
| SUBLOCADE | ~$1.1B 2024 revenue | High share, high growth |
| Channel | Controlled specialty pharmacy | Supports access and retention |
What is included in the product
Detailed Word Document
Indivior’s BCG matrix maps its portfolio into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page Indivior Pharmaceuticals BCG Matrix, quickly showing pain-point relievers by quadrant.
Reference Sources
Provides a traceable source trail for Indivior Pharmaceuticals Inc, boosting credibility and helping decision-makers verify key assumptions quickly.
Cash Cows
SUBOXONE Film: mature branded base
SUBOXONE Film is a mature legacy brand in a saturated opioid dependence market, so growth is limited but cash generation remains meaningful. Indivior’s recent filings show the product still carries scale and brand recognition, which supports steady revenue despite ongoing pressure from newer therapies. That profile fits classic Cash Cow behavior: low growth, strong installed base, and reliable cash flow.
SUBOXONE Tablet: legacy maintenance revenue
SUBOXONE Tablet is a legacy Indivior product with more than 20 years of commercial history, so its growth is now limited. Even with generic pressure and shifting prescribing toward newer forms, it can still throw off steady cash from a mature, stable maintenance market. That mix of high share, low growth, and recurring demand fits the Cash Cow spot in the BCG Matrix.
TRANSMUCOSAL BUPRENORPHINE FRANCHISE
Indivior’s transmucosal buprenorphine franchise is a mature oral maintenance business with broad prescriber familiarity and a large installed base, so it fits Cash Cow status. Growth is limited, but the category’s steady repeat use still supports cash generation; Indivior reported 2025 revenue of about $1.2 billion, with this franchise still a core contributor. Low market growth and entrenched usage make it a classic high-share, low-growth asset.
U.S. legacy OUD market
Indivior’s older U.S. OUD franchise still works like a Cash Cow: the market is mature, so spend can stay tight while repeat prescribing keeps sales steady. In 2025, this legacy base remained economically important even as growth shifted to newer therapies.
- Stable repeat prescribing
- Low promo intensity
- Entrenched treatment routines
- Cash-generating, low-growth mix
BRAND LOYALTY IN MAINTENANCE THERAPY
Indivior Pharmaceuticals Inc has a strong Cash Cow in maintenance therapy because prescribers and patients often stay with the same trusted brand once treatment is working. In mature opioid use disorder care, familiarity and continuity matter more than rapid growth, so brands like SUBLOCADE can keep demand steady and protect pricing power.
This kind of base usually needs less reinvestment than launch-stage products, so more of each sales dollar can turn into cash. That steady, low-churn profile is what makes maintenance therapy a classic Cash Cow.
- Long-term prescriber and patient ties support repeat use.
- Brand familiarity holds value in mature therapy.
- Stable demand helps margins and cash generation.
- Low reinvestment needs fit the Cash Cow profile.
Indivior’s Legacy OUD Brands Keep Generating Steady Cash
Indivior Pharmaceuticals Inc's Cash Cows are its legacy OUD brands, led by SUBOXONE Film and tablet, which sit in a mature market with steady repeat prescribing and weak growth. In 2025, Indivior reported about $1.2 billion in revenue, showing this base still converts scale into cash even as newer products drive growth. Low reinvestment and entrenched use make it classic Cash Cow territory.
| Asset | 2025 revenue | BCG role |
|---|---|---|
| Legacy OUD franchise | About $1.2 billion | Cash Cow |
Full Version Awaits
Indivior Pharmaceuticals Inc Reference Sources
The Indivior Pharmaceuticals Inc BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo version, no hidden changes—just the full, ready-to-use report. Download it instantly and use it for analysis, planning, or presentation.
Dogs
SUBUTEX Tablet: older mono-product
SUBUTEX is an older buprenorphine-only tablet with 2 mg and 8 mg strengths, and it has limited differentiation versus newer OUD options. In Indivior's 2025/2026 mix, growth is weak and pricing pressure is high, while broader products such as SUBLOCADE and SUBOXONE film carry more commercial pull. That makes SUBUTEX a clear Dog: low growth, weak strategic fit, and a shrinking role in a crowded OUD market.
ORAL MONO-BUPRENORPHINE SEGMENT
ORAL MONO-BUPRENORPHINE is a legacy, lower-priority line for Indivior Pharmaceuticals Inc, far behind long-acting injectables such as Sublocade. Prescribing is usually stable, but expansion is limited as the oral tablet market is mature and competitive. That weak growth and softer strategic fit point to the Dog quadrant.
GENERIC-HEAVY TABLET CHANNEL
Tablet-based opioid dependence therapy sits in a crowded generic field, so pricing power stays weak and share gains are hard to win. Indivior Pharmaceuticals Inc keeps this channel mainly for patient continuity, not growth, because low-margin tablet demand is pressured by cheaper substitutes. That mix of flat volume, thin economics, and heavy generic rivalry makes it a clear Dog in the BCG matrix.
SMALL U.K. LEGACY SALES
Indivior Pharmaceuticals Inc’s U.K. legacy sales are a small side business next to its U.S. opioid use disorder franchise, so they do not drive cash flow. Growth in the U.K. is limited, and the market is far smaller than the main U.S. addressable base. That profile fits Dog territory: low scale, low growth, and weak strategic weight.
- Small share of total sales
- Limited growth runway in U.K.
- Not the main cash engine
- Dog classification is justified
LOW-GROWTH NON-CORE INTERNATIONAL UNITS
Indivior’s low-growth non-core international units fit the Dog box because they add little scale and draw limited capital in a business that posted about $1.1 billion in net revenue in 2024, with growth still centered on the U.S. business. These lines are harder to expand, so management tends to keep attention on higher-return products like Sublocade and Opvee instead. In BCG terms, they usually have weak market share and low growth, so they are maintenance assets, not growth engines.
- Low scale, low strategic priority
- Weak fit with core growth drivers
- Limited impact on company-wide revenue
Indivior’s Legacy Dogs: Low Growth, Low Lift
Dogs are Indivior Pharmaceuticals Inc's legacy oral and regional lines: low growth, weak pricing, and small strategic weight. With about $1.1 billion in 2024 net revenue, management still leans on Sublocade and Opvee for growth, while these assets stay defensive and mature.
| Dog asset | Why it fits |
|---|---|
| SUBUTEX | Older tablet; weak growth |
| U.K. legacy sales | Small scale; low impact |
Question Marks
OPVEE: nalmefene nasal spray
OPVEE, Indivior Pharmaceuticals Inc's nalmefene nasal spray, is still early in commercialization, so its share is small even as the U.S. opioid overdose-reversal market stays large. U.S. drug overdose deaths were about 107,000 in 2023, so the upside is real. Adoption still depends on awareness, payer access, and clinician use, which makes OPVEE a classic Question Mark.
NALMEFENE NASAL SPRAY MARKET
Nalmefene nasal spray is still a small, developing opioid overdose category, unlike the established naloxone market. Indivior has a clear upside if prescriber and payer adoption broadens, but share is still uncertain because the category is not yet scaled. Until repeat use, access, and real-world uptake expand, it fits Indivior Pharmaceuticals Inc’s Question Mark slot.
OVERDOSE-REVERSAL ADOPTION
Indivior Pharmaceuticals Inc’s overdose-reversal push has clear strategic value, but it still lacks dominant scale. The U.S. saw about 80,391 drug overdose deaths in 2024, so the need is huge, and OPVEE can grow fast if pharmacy stocking and awareness improve. Still, its current reach is limited versus that public-health gap, so this fits a classic Question Mark.
SUBLOCADE OUTSIDE THE U.S.
SUBLOCADE outside the U.S. is a classic Question Mark: the product can scale from a low base if regulators, payers, and prescribers back it. Indivior's main cash engine is still the U.S., so international uptake is a small but real upside lever rather than a core profit pool.
That makes the path attractive but uncertain. If access improves in key markets, even modest share gains can matter; if reimbursement stays tight, growth stays limited.
- Low current non-U.S. share
- Upside depends on access
- Early launch curve, not mature
NEXT-GEN OUD PIPELINE
Indivior Pharmaceuticals Inc’s next-gen OUD pipeline is a Question Mark: it could lift long-term growth, but it still has limited scale and needs more capital plus clean execution. In 2025, the company’s base business still carried the load, so early assets must prove they can move from R&D spend to real revenue before Star status is realistic.
- Early-stage OUD assets: high upside
- Current scale: still too small
- Needs capital and execution
- Not yet a Star
OPVEE Remains a Question Mark as Adoption Stays Early
OPVEE stays a Question Mark for Indivior Pharmaceuticals Inc: the U.S. opioid overdose market is huge, but adoption is still early and share remains small. The U.S. recorded about 80,391 overdose deaths in 2024, so the upside is real. Still, payer access, stocking, and clinician use must improve before OPVEE can move out of this bucket. Non-U.S. SUBLOCADE and early OUD pipeline assets also fit here because scale is still limited and execution risk remains high.
| Asset | 2024/2025 signal | BCG role |
|---|---|---|
| OPVEE | Early launch, small share | Question Mark |
| Non-U.S. SUBLOCADE | Low base, access-led upside | Question Mark |
| OUD pipeline | R&D stage, no scale yet | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.